Yocon Biotech Officially Launches The Full Line of IPSC - Series Products

iPSC, short for induced pluripotent stem cells, is a type of cell with multi - directional differentiation potential obtained by introducing specific transcription factors into somatic cells to reprogram them. This miracul ous "reverse growth" through human intervention not only avoids embryo destruction but also enables every adult to become their own "stem cell bank".

In 2006, the same year when Yocon Biotech was founded, Japanese scientist Shinya Yamanaka used the exogenous gene over - expression technique to successfully reprogram mouse fibroblasts into iPSC cells for the first time. He won the Nobel Prize in Physiology or Medicine in 2012 for this ground - breaking achievement.

Before the creation of iPSC, embryonic stem cells received much attention as the cell source for regenerative medicine. However, due to the fact that their preparation process requires the sacrifice of human embryos, it has aroused huge ethical controversies. Human - derived iPSC cells not only have self - renewal and multi - directional differentiation abilities similar to those of embryonic stem cells, but also have no ethical problems caused by the use of aborted fetuses for embryonic stem cells. More importantly, these cells are directly derived from the patients themselves, which greatly reduces the risk of immune rejection and performs outstandingly in terms of immune adaptability and potential for individualized treatment. Because of this, in recent years, iPSC has attracted more and more attention in the field of cell therapy, whether in the scientific research community, the corporate sector, or at the capital level.

iPSC cells are known as "embryonic - like stem cells" and can differentiate into almost all types of functional cells in the human body, such as nerve cells, cardiomyocytes, liver cells, and islet cells. Nowadays, we have witnessed many examples of cells derived from iPSC being applied to the treatment of diseases: neural progenitor cells are used to treat Parkinson's disease, hepatic progenitor cells are used to treat acute liver injury, corneal epithelial cells are used to treat blindness, islet cells are used to treat type I diabetes, and iPSC is used for large - scale production of platelets for blood transfusion. With the gradual deepening of the understanding of the safety of iPSC - differentiated cells, the speed at which regulatory authorities approve iPSC - derived cell drugs is also accelerating. Currently, the cell drugs of many companies have entered the clinical phase II stage.

Yocon Biotech has long been committed to the research and development as well as production of serum - free culture products in the field of cell therapy. Since 2012, it has successively launched MSC - series products, immune - series products, engineered cell - series products, and assisted reproduction - series products. The newly launched iPSC - series products in 2025 have successfully filled the gap in the fifth of the six product segments.

This series of products covers the core products for iPSC cell expansion and culture, including iPSC serum - free medium, iPSC - specific cell cryopreservation solution, and iPSC - specific cell digestion enzyme. It also includes the basic medium and supporting reagents for the subsequent differentiation and culture of iPSC cells. The iPSC - series products of Yocon Biotech will provide reliable supply chain support with high quality, controllable cost, and complete product line for enterprises and research institutions engaged in the development of iPSC products, helping to promote the further development of the iPSC cell therapy field.

List of Yocon Biotech's full - line iPSC products